source
- Connect Biopharma's asthma drug rademikibart misses primary endpoint in Phase 2 trialConnect Biopharma reported that its IL-4/IL-13 blocker rademikibart failed to meet the primary endpoint in a Phase 2 study in asthma patients with type-2 inflammation. The trial enrolled 160 patie…
- Novo abandons $285 million partnership with Ascendis for monthly GLP-1 obesity drugNovo Nordisk, which recently rebranded, has terminated a licensing agreement with Ascendis Pharma that was originally valued at up to $285 million. The collaboration, signed in November 2024, was…